Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GH Research ( (GHRS) ) just unveiled an update.
GH Research PLC announced the presentation of data from its GH001-TRD-201 clinical trial at the 38th European College of Neuropsychopharmacology annual meeting, held from October 11-14, 2025, in Amsterdam. The presentations, scheduled for October 13 and 14, 2025, will showcase the psychoactive effects, safety, and tolerability of GH001 in patients with treatment-resistant depression, potentially impacting the company’s position in the mental health treatment market.
The most recent analyst rating on (GHRS) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC is a company operating in the pharmaceutical industry, focusing on the development of novel treatments for mental health disorders. Their primary product, GH001, is aimed at addressing treatment-resistant depression, a significant area of unmet medical need.
Average Trading Volume: 307,414
Technical Sentiment Signal: Buy
Current Market Cap: $816.9M
See more insights into GHRS stock on TipRanks’ Stock Analysis page.